Skip to main content
Equibles
CNTX logo

CNTX · Context Therapeutics Inc. · Metrics

Track CNTX — free

Use CNTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CNTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.25 +0.01 (+2.77%)
Russell 2000 member Rebalance outlook locked
Market Cap
$22.40M
Shares
91.88M
Volume · Oct 20 723.94K Avg daily vol (3M) 1.55M

CNTX metrics

67 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.24
Market cap
$22.40M

Price action

20 metrics
Price change (1W)
-21.8%
Price change (30D)
-36.4%
Price change (3M)
-61.3%
Price change (6M)
-89.5%
Price change (YTD)
-83.8%
Price change (1Y)
-83.4%
Trailing year
Price change (5Y)
—
52-week high
$3.36
52-week low
$0.24
Change from 52-week high
-92.9%
Change from 52-week low
+0.0%
Annualized volatility
102.8%
Annualized volatility (3M)
86.7%
Beta
0.3
RSI (14D)
25.5
Price vs SMA 50
-36.6%
Price vs SMA 200
-84.3%
Avg volume (3M)
1.56M
Relative volume
0.5
Average dollar volume
$699,876

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
91.88M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.6
reciprocal yield 174.3%
FCF yield
-155.3%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-209.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-06-15

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$48.73M
Net income (TTM)
−$45.96M
Trailing 12 months
Diluted EPS (TTM)
$-0.48
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-0.51
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-0.48
Operating cash flow per diluted share (TTM)
$-0.36
Free cash flow per diluted share (TTM)
$-0.36
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$0.42
Stock compensation per diluted share (TTM)
$0.02
Book value per share
$0.66

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
0.0%
Year over year · fewer shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-120.4%
Return on assets
-99.6%
Debt / equity
0.0
Current ratio
5.8
EBITDA (TTM)
—
Free cash flow (TTM)
−$34.03M
Quick ratio
5.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$42.99M
Latest balance sheet
Cash & equivalents
$42.99M
Total assets
$46.13M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$33.97M
Capital expenditures (TTM)
$55,746
R&D (TTM)
$40.11M
SG&A (TTM)
—
Stock compensation (TTM)
$1.59M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
79
13F filer change QoQ
+18
Institutional ownership
68.4%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
29.7%
Private-fund adviser ownership
20.8%
Active holders' share change QoQ
-29.1%
Holder tenure
6.5
Price vs estimated holder cost
-71.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
8.7%

Short interest

3 metrics
Short interest
5.1%
Latest settlement · 4.0 days to cover
Days to cover
4.0d
Short-squeeze score
46 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1842952 CUSIP 21077P108 13F (30d) 10 filings 10 filers Visit website Investor relations